The President and CEO of PPTA visits the Bolognana plant

On March 11th, Anita Brikman, President and CEO of the Plasma Protein Therapeutics Association (PPTA), along with Maarten Van Baelen, Executive Director of PPTA Europe, visited our production plant in Bolognana in the province of Lucca.

PPTA is a key player in the global plasma industry, representing an extensive network of human plasma collection centers and plasma-derived therapies manufacturers.

Our Bolognana facility is a vertically integrated plant where every phase of plasma derivative production is carried out. Its plasma fractionation capacity is 1.1 million liters per year, producing almost five million drugs each year for distribution in around 100 countries around the world. The site employs 570 people.

Considering our solid partnership with PPTA – of which we have been members since its foundation – the visit was an opportunity to consolidate the relationship of strategic cooperation, firstly, to expand patients’ access to the plasma-derived therapies they need worldwide. 

During the visit, Paolo Marcucci, Chairman of the company, and our CEO Ugo Di Francesco, discussed the various scenarios related to the plasma derivative field, with particular attention to the new and multiple challenges that the industry world and the patient community are called to face together today.

“Today I had the opportunity to visit and get to know up close the Kedrion site in Bolognana, a cutting-edge plant that combines quality with production efficiency and technological innovation,” said Anita Brikman at the end of the visit. “This impressive facility and its output perfectly reflects Kedrion’s commitment to providing increasingly effective and personalized therapeutic solutions”.

“This meeting,” declared our Chairman Paolo Marcucci, “confirms and strengthens the synergy and cooperation that has always characterized the relationship between Kedrion and PPTA. This partnership reflects the common commitment to ensure adequate and safe availability of plasma-derived treatments for patients around the world”.

Our CEO Ugo Di Francesco stated: “During the day, we explained our reality in detail, giving ample space to projects and activities that reflect our ongoing commitment to those living with rare and ultra-rare diseases and who require constant dialogue and discussion with public institutions and decision makers at national and international level”.

For more information please contact: [email protected]